Ascendis Pharma Reports Q3 2024 Financial Results
Ticker: ASND · Form: 6-K · Filed: Nov 14, 2024 · CIK: 1612042
Sentiment: neutral
Topics: financial-results, 6-K, earnings
TL;DR
Ascendis Pharma dropped Q3 2024 earnings today via 6-K, check the press release for details.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on November 14, 2024, to report its financial results for the fiscal quarter ended September 30, 2024. The filing includes a press release detailing these results.
Why It Matters
This filing provides investors with the latest financial performance data for Ascendis Pharma, crucial for evaluating the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new risks.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- November 14, 2024 (date) — Filing Date
- September 30, 2024 (date) — Quarter End Date
FAQ
What type of report is Ascendis Pharma A/S filing?
Ascendis Pharma A/S is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What period do the financial results in the press release cover?
The press release reports financial results for the fiscal quarter ended September 30, 2024.
When was this Form 6-K filed?
This Form 6-K was filed on November 14, 2024.
What is the principal executive office address for Ascendis Pharma A/S?
The address is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F?
Yes, Ascendis Pharma A/S indicates it files annual reports under Form 20-F.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-11-14 16:19:49
Filing Documents
- d827238d6k.htm (6-K) — 9KB
- d827238dex991.htm (EX-99.1) — 117KB
- g827238g1115010800056.jpg (GRAPHIC) — 3KB
- g827238g1115010800386.jpg (GRAPHIC) — 1KB
- 0001193125-24-258608.txt ( ) — 133KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: November 14, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer